Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. - Wikidata - awgldk - TriplyDB

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

http://www.wikidata.org/entity/Q33793770

about

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens Fluorescence correlation spectroscopy as a sensitive and useful tool for revealing potential overlaps between the epitopes of monoclonal antibodies on viral particles.Alternative administration routes and delivery technologies for polio vaccines.Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles.

P2860

Q36500269-02998D8A-47C4-46C4-B13E-27E46DE97D58 Q37327302-76ED36E6-3F35-4094-83D4-3707E76D2847 Q38748979-2AF33EC8-91DD-459A-99A6-F4396C0B41E2 Q40563756-13000F9D-1F7D-4C23-B580-EDFAF53C98BE Q40694023-0663FC00-01B4-4245-9D58-2C81B34260F3

P2860

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

http://www.wikidata.org/entity/Q33793770

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

@ast

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

@en

type

label

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

@ast

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

@en

prefLabel

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

@ast

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

@en

P1433

Q33793770-1B85EFD3-CA8C-498F-916C-3E82C1A07F73

P1476

Q33793770-058945EA-C9DC-47CE-A9FB-39F844BA332F

P2093

Q33793770-05B2DA30-1E44-4E2A-BB50-A6E949369086

Q33793770-40BE4B4E-81B5-453F-B0CA-FF2EFA99E917

Q33793770-A7CCF1A3-7AAF-4033-9D61-3B02D2776D4C

P2860

Q33793770-1479A9B0-14CD-426B-BFED-C47E6AB20364

Q33793770-15070F27-77C3-440C-AA83-4097A7FC4A4C

Q33793770-19F69459-63A4-4CF5-94DE-7E7465B9D6A5

Q33793770-1B392F29-3E5F-4BC7-BA16-E1C24A839863

Q33793770-21AA9135-6A34-44F7-AC60-17764473BFC2

Q33793770-22A20E36-96F9-441C-9BD4-1D58FE3DCE5E

Q33793770-2CC491EA-C515-443D-8A3B-931E7A9DBFFD

Q33793770-2E02C0EA-2A24-4B49-8F8A-BF51A3FB3B44

Q33793770-31EA5B24-F3D0-48F1-83B5-40BCB8092A25

Q33793770-3F7AC05B-8317-4FBE-B9BA-A7F854049BD3

P304

Q33793770-3600D5F8-4FB5-48DC-B5D1-5095F70B5BC1

P31

Q33793770-64377564-B59E-428A-8244-91DB1ACA7663

P356

Q33793770-020B3BFB-D515-4034-B395-32784CB03C89

P407

Q33793770-98C44B17-7233-4FAB-8001-6A8A58BAF1D7

P433

Q33793770-1D4966A0-4F27-4C5B-8440-A8D20EA979F3

P478

Q33793770-6096AAD0-892D-4A6E-AB30-B7EFD61A388F

P50

Q33793770-BC5EF564-E62D-4ED0-92E3-54095BC36285

P577

Q33793770-3190DFD7-AD0C-4DC0-AF60-0399F158F1B6

P5875

Q33793770-EEED6BCA-51F8-4B2E-9256-FC1EAFF8EFDD

P698

Q33793770-664EE35E-C485-4ABF-B3C1-8F527E0D9081

P932

Q33793770-DA646D05-F103-4FAF-B6DA-5E8EDC369A69

P356

JOURNAL.PONE.0100879

P1433

P1476

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

@en

P2093

Else Marie Agger

http://www.w3.org/2001/XMLSchema#string

Jes Dietrich

http://www.w3.org/2001/XMLSchema#string

Lars Vibe Andreasen

http://www.w3.org/2001/XMLSchema#string

P2860

VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION *

Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes

The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity

CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets

A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes.

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.

Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model.

P304

e100879

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0100879

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263356116

http://www.w3.org/2001/XMLSchema#string

P698

24956110

http://www.w3.org/2001/XMLSchema#string

P932

4067388

http://www.w3.org/2001/XMLSchema#string